FindMyKOL
Clinical trialNCT03921242CompletedObservational

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

NCT03921242 is an observational study sponsored by Weill Medical College of Cornell University. As of 18 Nov 2026, it is completed. It studies DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and 1 more drug in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic. The registry lists an enrollment of 4,888 participants at 2 sites in 1 country. The registry lists a start date of 1 Aug 2019 and a primary completion date of 1 Aug 2023.

SponsorWeill Medical College of Cornell University →Enrollment4,888Diabetes Mellitus, Type 2Renal Insufficiency, Chronic
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03921242
FieldValue
Registry IDNCT03921242
StatusCompleted
Study typeObservational study
Lead sponsorWeill Medical College of Cornell University
Enrollment4,888
Registered sites2
Countries1
ConditionsDiabetes Mellitus, Type 2 and Renal Insufficiency, Chronic
DrugsDPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and Sulfonylurea
Start1 Aug 2019
Primary completion1 Aug 2023
Study completion1 Aug 2023
Last update posted9 Nov 2023

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a proposal for a retrospective observational study of the safety of metformin use in patients with chronic kidney disease, compared to other commonly used diabetes drugs. It will be conducted using retrospective data from the New York City CDRN, Medicare administrate files, and New York State Medicaid administrative files, which will be linked and then deidentified prior to analysis.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Alvin Mushlin

    Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

North Carolina, United States1 site
  • University of North Carolina

    Chapel Hill

Tennessee, United States1 site
  • Vanderbilt University Medical Center

    Nashville

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 1 siteTN1North Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DPP-4 inhibitorGLP1 receptor agonistMetformin →SGLT2 inhibitorSulfonylurea
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03921242

Each answer restates registry values shown on this page.

What is NCT03921242?

NCT03921242 is an observational study sponsored by Weill Medical College of Cornell University. It studies DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and 1 more drug in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic.

Who leads NCT03921242?

The registry names Alvin Mushlin (principal investigator, Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center) as the overall official.

Where does NCT03921242 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03921242 study?

The registered drug and biological interventions are DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and Sulfonylurea.

When did NCT03921242 end?

The registry lists a primary completion date of 1 Aug 2023 and a study completion date of 1 Aug 2023. The sponsor last updated the record on 9 Nov 2023.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.